GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (NAS:SLNO) » Definitions » PB Ratio

Soleno Therapeutics (Soleno Therapeutics) PB Ratio : 10.73 (As of May. 18, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Soleno Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-18), Soleno Therapeutics's share price is $46.16. Soleno Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $4.30. Hence, Soleno Therapeutics's PB Ratio of today is 10.73.

The historical rank and industry rank for Soleno Therapeutics's PB Ratio or its related term are showing as below:

SLNO' s PB Ratio Range Over the Past 10 Years
Min: 0.02   Med: 0.61   Max: 10.62
Current: 10.62

During the past 12 years, Soleno Therapeutics's highest PB Ratio was 10.62. The lowest was 0.02. And the median was 0.61.

SLNO's PB Ratio is ranked worse than
90.14% of 1318 companies
in the Biotechnology industry
Industry Median: 2.555 vs SLNO: 10.62

During the past 12 months, Soleno Therapeutics's average Book Value Per Share Growth Rate was 1231.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -16.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -25.70% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Soleno Therapeutics was -5.90% per year. The lowest was -38.50% per year. And the median was -28.40% per year.

Back to Basics: PB Ratio


Soleno Therapeutics PB Ratio Historical Data

The historical data trend for Soleno Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics PB Ratio Chart

Soleno Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.78 3.37 1.84 1.56 8.10

Soleno Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.63 3.43 19.66 8.10 9.95

Competitive Comparison of Soleno Therapeutics's PB Ratio

For the Biotechnology subindustry, Soleno Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soleno Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soleno Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Soleno Therapeutics's PB Ratio falls into.



Soleno Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Soleno Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=46.16/4.301
=10.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Soleno Therapeutics  (NAS:SLNO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Soleno Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Soleno Therapeutics (Soleno Therapeutics) Business Description

Traded in Other Exchanges
Address
203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome.
Executives
Patricia C Hirano officer: See Remarks 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Kristen Yen officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
Bhatnagar Anish director, officer: See Remarks 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065
James H Mackaness officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Abingworth Bioventures Vii Lp 10 percent owner PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505